Financial & Investment Management Group Ltd. Has $7 Million Position in Merck & Co., Inc. (MRK)

Financial & Investment Management Group Ltd. lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 11.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,667 shares of the company’s stock after selling 11,687 shares during the period. Merck & Co., Inc. accounts for approximately 2.6% of Financial & Investment Management Group Ltd.’s portfolio, making the stock its 7th largest holding. Financial & Investment Management Group Ltd.’s holdings in Merck & Co., Inc. were worth $7,004,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of MRK. WESPAC Advisors SoCal LLC bought a new stake in shares of Merck & Co., Inc. in the third quarter worth $118,000. Prentiss Smith & Co. Inc. increased its stake in shares of Merck & Co., Inc. by 17.1% in the third quarter. Prentiss Smith & Co. Inc. now owns 4,793 shares of the company’s stock worth $340,000 after buying an additional 700 shares during the last quarter. Stillwater Capital Advisors LLC boosted its holdings in Merck & Co., Inc. by 0.9% in the third quarter. Stillwater Capital Advisors LLC now owns 248,579 shares of the company’s stock worth $17,634,000 after purchasing an additional 2,249 shares during the period. Spinnaker Trust boosted its holdings in Merck & Co., Inc. by 3.6% in the third quarter. Spinnaker Trust now owns 64,891 shares of the company’s stock worth $4,603,000 after purchasing an additional 2,233 shares during the period. Finally, M. Kraus & Co boosted its holdings in Merck & Co., Inc. by 12.7% in the third quarter. M. Kraus & Co now owns 8,855 shares of the company’s stock worth $628,000 after purchasing an additional 1,000 shares during the period. Institutional investors own 72.55% of the company’s stock.

In other news, Director Thomas H. Glocer sold 10,000 shares of the business’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $75.96, for a total transaction of $759,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Kenneth C. Frazier sold 231,566 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $78.08, for a total transaction of $18,080,673.28. Following the transaction, the chairman now directly owns 923,516 shares of the company’s stock, valued at approximately $72,108,129.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 709,324 shares of company stock valued at $56,162,582. Corporate insiders own 0.32% of the company’s stock.

A number of equities analysts have commented on MRK shares. Citigroup set a $65.00 price objective on shares of Merck & Co., Inc. and gave the stock a “hold” rating in a report on Thursday, December 20th. Zacks Investment Research downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 24th. BMO Capital Markets downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective for the company. in a report on Wednesday, January 23rd. Morgan Stanley set a $81.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, December 20th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 4th. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and an average target price of $77.06.

Shares of MRK opened at $81.57 on Friday. Merck & Co., Inc. has a 1 year low of $52.83 and a 1 year high of $82.12. The firm has a market cap of $219.71 billion, a PE ratio of 18.79, a PEG ratio of 1.99 and a beta of 0.62. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.17 and a quick ratio of 0.92.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, February 1st. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 36.83%. The company had revenue of $11 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the previous year, the company posted $0.98 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. On average, analysts anticipate that Merck & Co., Inc. will post 4.65 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.70%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2019/03/17/financial-investment-management-group-ltd-has-7-million-position-in-merck-co-inc-mrk.html.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Further Reading: The Discount Rate – What You Need to Know

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply